FC
ESPR icon

Farringdon Capital’s Esperion Therapeutics ESPR Stock Holding History

Farringdon Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,514
Closed -$19.5K – 477
2025
Q1 		$19.5K Buy
+13,514
New +$24.9K 0.01% 321

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Farringdon Capital's ESPR Position: Q2 2025 in Review

Farringdon Capital sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 13,514 shares — an estimated $19.5K sold.

Farringdon Capital first reported a position in ESPR in Q1 2025 and held it in 1 quarter. The position peaked at $19.5K in Q1 2025. 164 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Farringdon Capital reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Farringdon Capital sold 13,514 Esperion Therapeutics shares in Q2 2025, an estimated $19.5K.
  • Farringdon Capital first reported a position in Esperion Therapeutics in Q1 2025 and held it in 1 quarter.
  • Farringdon Capital's Esperion Therapeutics position peaked at $19.5K in Q1 2025.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Farringdon Capital's 13F filing for Q2 2025, filed 14 Aug 2025.